Epidemiological Analysis of Confirmed Mpox Cases in Burundi, July to September 2024

Alexis Nizigiyimana[1#], Francois Ndikumwenayo[2], Martin Manirakiza[2,3], Monique van Lettow[4,5], Sarah Houben[6], Laurens Liesenborghs[6], Placide Mbala-Kingebeni[7,8], Anne W. Rimoin[9], Isaac I. Bogoch[10], Jason Kindachuk[11,12#]

[1]Department of Management, Evaluation and Health Policy, School of Public Health, Université de Montréal, Montreal, QC, Canada

[2]University of Burundi, Bujumbura, Bujumbura, Burundi

[3]Burundi NCD Alliance, Bujumbura, Burundi

[4]Madiro, Toronto, Canada.

[5]Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

[6]Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

[7]Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo

[8]Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa

[9]Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA

[10]Department of Medicine, University of Toronto, Toronto, ON, Canada

[11]Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada

[12]Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

#Corresponding Authors: Alexis Nizigiyimana (alexis.nizigiyimana@madiro.org); Jason Kindrachuk (Jason.Kindachuk@umanitoba.ca)

ABSTRACT

This study analyzes mpox cases in Burundi from July to September 2024, following the introduction of Clade Ib. During this time, 25.4% of 607 samples tested positive via PCR. Children under 15 comprised 55.2% of cases, with a higher proportion of female children testing positive. Geographic analysis demonstrates case concentration in Bujumbura Mairie (59.1%). These findings highlight the importance of age- and sex-specific interventions for outbreak containment and the need for targeted public health strategies in Burundi.

INTRODUCTION

Mpox is a zoonotic viral infectious disease first identified in the Democratic Republic of the Congo (DRC) in 1970 (1-3). Monkeypox virus (MPXV) historically circulated in the tropical forest regions of Central and West Africa, where it is considered endemic (4, 5). The virus is subclassified into two clades: clade I, formerly known as the Congo Basin (Central Africa) clade, and clade II, formerly known as the West African clade. Clade II is further subdivided into two subclades: IIa and IIb, with the latter responsible for the global epidemic in 2022 (6, 7).

Historically, zoonosis has been the primary driver of MPXV infections in humans with secondary infections through human-to-human contact. However, Clade IIb MPXV infections during the 2022 global epidemic were linked primarily to sustained human-to-human transmission (8) including within the men who have sex with men (MSM) community (9). The emergence of Clade Ib MPXV in South Kivu, DRC, has demonstrated similar transmission characteristics that have included linkage to sexual networks and sustained human-to-human transmission (10). However, unlike Clade IIb infections, Clade Ib mpox cases have not been overrepresented among males in South Kivu. Further, recent expansion of Clade Ib into North Kivu, DRC, has included probable transmission through non-sexual or intimate contacts that have included children. While there may be reporting biases complicating a more wholesome understanding of mpox epidemiology, containment and mitigation strategies in this ongoing public health emergency must also consider the context-dependencies of these differences.

Here, we provide an analysis of demographic and epidemiological considerations for mpox in Burundi using mpox case data from July to September 2024.

RESULTS

We analyzed national mpox testing and demographic data acquired in Burundi from 03 July 2024 to 09 September 2024 (week 27 to week 37). During this period, a total of 607 samples were tested by PCR for MPXV (Figure 1). Of these, men comprised 305 samples (50.2%) and women comprised 302 samples (49.8%). For all samples, 154 samples (25.4%) tested positive, 448 samples (73.8%) tested negative, and 5 samples (0.8%) were indeterminate. Of the positive samples, most positive tests were from men (80/154; 51.9%) with women comprising 48.1% of positive cases (74/154).

In analyzing age demographics, the median age of all individuals tested was 7 years (IQR: 2-18 years) (Figure 2). For mpox-positive cases, the median age was 9.5 years (IQR: 3-25 years). For males, the median age of positive cases was 17.5 years (IQR: 4.8-28.5 years). In contrast, the median age of females who tested positive was 6 years (IQR: 2-20 years).

In analyzing overall age demographics with mpox positivity, children <15 years comprised the majority of all positive cases (85/154; 55.2%) (Table 3). This was followed by those aged 15-30 years (45/154; 29.2%) and lastly individuals 30+ years (24/154; 15.6%). When factoring in sex and age with mpox positivity, there was a greater proportion of females (47/154; 30.5%) than males (38/154; 24.7%) for children <15 years. Proportions were comparable between females and males for those 15-30 years at 13.6% (21/154) and 15.6% (24/154), respectively. For those aged 30+ years, there was a greater proportion of males (18/154; 11.7%) than females (6/154; 3.9%).

We also assessed the geographic distribution of positive cases in Burundi (Figure 3). Mpox positive cases were identified from 14 provinces in Burundi with the majority of positive cases identified in Bujumbura Mairie (91/154; 59.1%) followed by Bubanza, Bujumbura, and Kayanza with 10 cases reported from each (6.5% of positive cases). Associations between geographic regions and age distribution of cases were limited due to the high proportion of overall mpox cases reported from Bujumbura Mairie and much lower proportions in any of the other provinces reporting. We did analyze age demographics in Bujumbura Mairie as compared to the complete national data set. When focusing on Bujumbura Mairie, where 59.1% (91/154) of all mpox cases

were reported, children <15 years comprised 45% of cases (44/91), followed by those aged 15-30

years at 35.2% (32/91) and lastly those 30+ years with 16.5% of cases (15/91). When combining

positive case data from all other provinces (63 cases total), children <15 years comprised the

highest proportion of all cases at 65.1% (41/63), followed by those aged 15-30 years at 20.6%

(13/63) and those 30+ years at 14.3% (9/63).

Hospitalization data for confirmed mpox cases was available up to 25 September 2024 for a total

of 254 cases with 247 requiring care for more than one day (Table 1). The median age of those

hospitalized was 19 (IQR: 8-28) with females being younger than males at 16 years (IQR: 7-25)

versus 22 (IQR: 8-32), respectively. The overall duration of hospital admission was 8 days (IQR:

6-12) with females and males having very similar hospitalization durations at 8 days (IQR: 5-

9.8) and 9 days (IQR: 6-12), respectively. No deaths were recorded though 45 patients remained

hospitalized at the time of this report. The majority of patients has no known comorbidities. For

hospitalized females, HIV positivity was noted among 6 patients, followed by hypertension (3

cases), asthma (2 cases), and diabetes (1 case). For the hospitalized males, the most prominent

comorbidities were hypertension (4 cases), asthma (3 cases), diabetes (3 cases), and HIV (1

case).

DISCUSSION

From January 2023 to present, broad geographic expansion of Clade I MPXV in the DRC has

resulted in the largest mpox outbreak in recorded history among all endemic countries.

Concerningly, this national outbreak has included the expansion of MPXV to all provinces in

DRC as well as the emergence of a new virus subclade, Clade Ib, associated with sustained

human-to-human transmission (10). While first reported in South Kivu province, DRC, Clade Ib

has undergone rapid regional expansion that has included introduction to North Kivu, DRC (11),

as well as dissemination to neighbouring countries in East Africa, including Uganda, Rwanda,

Kenya, and most notably Burundi.

Here, we provide the first assessments of demographic, epidemiological, and hospitalization data

from suspected and confirmed mpox cases in Burundi from 03 July 2024 to 09 September 2024.

During this period, 607 suspected mpox cases underwent PCR testing with an overall mpox

positivity rate of 25.4%. This report provides important insights into Clade Ib mpox cases. Sex-
specific differences were present when considering age, mpox positivity, and hospitalization.
While the median ages of males and females were very similar among mpox negative cases (7
years and 6 years, respectively) there was a large median age difference between males and
females for mpox positive cases (17.5 years and 6 years, respectively), highlighting potential
disparate sex-based epidemiologic risk factors for infection. When considering hospitalization,
females with mpox tended to be younger than males (16 years compared to 22 years); however,
the durations of hospitalization were very similar at 8 days and 9 days, respectively. Importantly,
no fatalities were noted among these patients though there were individuals still hospitalized at
the time of this reporting. These data provide important considerations for mpox response and
containment efforts in Burundi. Notably, this early epidemiological data suggests that female
children may be at higher risk for infection acquisition than their male counterparts whereas
males >30 years appear to be at higher risk for infection than females. Whether these data are
reflective of certain activities or behaviours associated with greater risk of MPXV infection
across sex and age groups needs to be addressed. An additional important consideration from this
data is that while mpox cases in Burundi were overrepresented among children <15 years, the
median age of hospitalization for both males and females was >15 years. Considerations should
include assessment of potential reporting biases by sex and age as well as activities among these
groups that may be associated with higher infection risks (e.g. household caregiving, contact
with contaminated materials). It is also prudent to consider recent data from North Kivu which
included probable non-sexual (intimate) contact-based transmission events within and outside of
households, including children (11). Thus, community engagement and messaging activities in
Burundi should consider these early associations between mpox positivity status, sex, and age.

This report provides an early assessment of the demographic and epidemiological characteristics
of Clade Ib mpox cases in Burundi and provide important insights for ongoing outbreak
containment and mitigation strategies, including community engagement and messaging
activities.

ETHICS STATEMENT

Data was provided by country-wide mpox surveillance program. Permission to use this data was
granted by the Institutional Ethics Committee at the Faculty of Medicine, University of Burundi
(CIEB-FMCHUK no. 02/09/2024).

DATA AVAILABILITY

154 All data produced in the present study are available upon reasonable request to the authors.

FUNDING

157 Funding for the work presented was provided by the International Mpox Research Consortium
158 (IMReC) through funding from the Canadian Institutes of Health Research and International
159 Development Research Centre (grant no. MRR-184813) and the European and Developing
160 Countries Clinical Trials Partnership (EDCTP) (Project 101195465-Mbote-SK)

CONFLICT OF INTEREST

163 IIB consults to the Weapons Threat Reduction Program at Global Affairs Canada. LL has
164 consulted for BioNTech.

REFERENCES

1.   Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human
monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165-82.
2.   Foster SO, Brink EW, Hutchins DL, Pifer JM, Lourie B, Moser CR, et al. Human
monkeypox. Bull World Health Organ. 1972;46(5):569-76.
3.   Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in
Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ.
1972;46(5):593-7.

4.   Van Dijck C, Hoff NA, Mbala-Kingebeni P, Low N, Cevik M, Rimoin AW, et al.

Emergence of mpox in the post-smallpox era-a narrative review on mpox epidemiology. Clin

Microbiol Infect. 2023;29(12):1487-92.

5.   Okwor T, Mbala PK, Evans DH, Kindrachuk J. A contemporary review of clade-specific

virological differences in monkeypox viruses. Clin Microbiol Infect. 2023;29(12):1502-7.

6.   Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R, et al. New

nomenclature for mpox (monkeypox) and monkeypox virus clades. Lancet Infect Dis.

2023;23(3):273-5.

7.   Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al.

Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med.

2022;387(8):679-91.

8.   WHO. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends. 2023.

9.   Tarin-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suner C, Anton A, et al. Clinical

presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a

prospective observational cohort study. Lancet. 2022;400(10353):661-9.

10.   Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole A, Wawina-Bokalanga T,

Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern

Democratic Republic of the Congo. Nat Med. 2024.

11.   Mukadi-Bamuleka D K-LE, Mulopo-Mukanya N, Amuri-Aziza A, O'Toole A et al. First

imported Cases of MPXV Clade Ib in Goma, Democratic Republic of the Congo: Implications

for Global Surveillance and Transmission Dynamics. medRxiv. 2024.

FIGURES AND TABLES:

Figure 1: Demographics of mpox test results in Burundi from week 27 to week 37. A) mpox cases by result and week of reporting; B) mpox cases by sex during reporting period; C) mpox cases by sex and week of reporting; D) mpox testing results by sex during reporting period.

C.

Week	Sexe	cases
2024-W27	Female	3
2024-W27	Male	4
2024-W29	Male	1
2024-W30	Female	1
2024-W30	Male	2
2024-W32	Female	21
2024-W32	Male	31
2024-W34	Female	4
2024-W34	Male	4
2024-W36	Female	40
2024-W36	Male	33
2024-W37	Female	5
2024-W37	Male	5

D.

	Negative	Indeterminate	Positive
Male	223 (49.8%)	2 (0.33%)	80 (13.2%)
Female	225 (50.2%)	3 (0.49%)	74 (12.2%)
Total	448 (73.8%)	5 (0.82%)	154 (25.4%)

Figure 2: Age demographics for individuals tested for mpox in Burundi from week 27 to week 37. A) Mpox positive cases by age group and week of reporting; B) total mpox cases by age group during reporting period; C) Median ages of mpox cases by sex.

A.

B.

Age_group	cases
0-17	91
18-44	57
45-64	4
65+	2

C.

	Positive Median Age (years)	Negative Median Age (years)
Male	17.5 (IQR: 4.8-28.5)	7 (IQR: 2-17.5)
Female	6 (IQR: 2-20)	6 (IQR: 2-14)
Total	9.5 (IQR: 3-25)	6 (IQR: 2-15)

222 **Figure 3: Mpox case mapping in Burundi from week 27 to week 37.** A) Total mpox cases by

223 province during reporting period. B) Total mpox cases by week across all provinces; C) Total

224 cases by province (numerical); D) Total mpox cases by community during reporting period; E)

225 Total mpox cases by week across communities during reporting period.

227   **Table 1: Hospitalization data in Burundi up to 25 September 2024.**

	Total Hospitalizations	**Median Age (years)**	**Duration of Care (days)**
Male	**132**	22 (IQR: 8-32)	9 (IQR: 6-12)
Female	**115**	16 (IQR: 7-25)	8 (IQR: 5-9.8)
Total	**247**	19 (IQR: 8-28)	8 (IQR: 6-12)